As of Oct 21
| +0.012 / +2.26%|
The 1 analysts offering 12-month price forecasts for Mateon Therapeutics Inc have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 2.00. The median estimate represents a +268.94% increase from the last price of 0.54.
The current consensus among 1 polled investment analysts is to Buy stock in Mateon Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.